Patents Assigned to Baxalta Incorporated
  • Syringe storage tray
    Patent number: 9889248
    Abstract: A storage tray for one or more syringes includes a recess for each of the syringes to be held in the tray. Each recess has first and second opposed sidewalls that define a space therebetween for receiving the barrel of the syringe. Each of the first and second sidewalls has one or more deformable projections thereon that protrude into the space between the sidewalls for positively retaining the barrel of the syringe between the first and second sidewalls. Additionally, a slot is provided for receiving the thumb rest of the plunger. The slot includes a third sidewall oriented generally transverse to the first and second sidewalls, with the third sidewall including a further projection for engaging a surface of the thumb rest. Preferably, a plurality of such transverse slots is provided to accommodate different positions of the plunger relative to the syringe barrel.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 13, 2018
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Brian R. Head, Amy R. Cohen, Georgios A. Bertos, Michael P. Wehrli, Atif M. Yardimci, David V. Alizo, Joseph S. Moore, Mark E. Williamson
  • TFPI inhibitors and methods of use
    Patent number: 9873720
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 23, 2018
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
  • Production of fully processed and functional factor X in a furin-secreting mammalian expression system
    Patent number: 9873892
    Abstract: Disclosed herein are methods for production of fully-processed mature Factor X in an expression system producing a controlled amount of furin between 50 U/mL and 300 U/mL of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and Factor X.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 23, 2018
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Ernst Böhm, Franziska Horling, Jadranka Koehn, Michael Dockal
  • Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
    Patent number: 9855331
    Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of immunoglobulins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: January 2, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Harald Arno Butterweck, Bernhard Kölbl, Lucia Hofbauer, Wolfgang Teschner, Hans-Peter Schwarz
  • FORMULATION OF SUGAR SOLUTIONS FOR CONTINUOUS ULTRACENTRIFUGATION FOR VIRUS PURIFICATION
    Publication number: 20170369853
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Application
    Filed: July 11, 2017
    Publication date: December 28, 2017
    Applicants: Baxalta Incorporated, Baxalta GmbH
    Inventors: Manfred REITER, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Method of producing recombinant high molecular weight vWF in cell culture
    Patent number: 9834591
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 5, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
  • IgG stimulated remyelination of peripheral nerves
    Patent number: 9834593
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 5, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Syringe storage tray
    Patent number: 9808570
    Abstract: A storage system is provided. The system may include a tray having at least one recess in which at least one syringe is disposed, the syringe including a barrel with first and second barrel ends, and a stopper fixedly disposed between the first and second barrel ends. A tool attached to the stopper through the second barrel end, the tool having a first end attached to the stopper and a second end attached to or abutting the barrel or a surface of the recess, the first end being selectively adjustable relative to the second end to vary the distance between the first and second ends of the tool. In addition or in the alternative to the tool, the system may include a motion generator attached externally to the syringe, the motion generator being one of at least a vibration generator and a rotating frame.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: November 7, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Brian R Head, Mark E Williamson, Michael P Wehrli, Joseph J. Kircher, Michelle L. Moran, Atif M. Yardimci
  • Animal protein-free media for cultivation of cells
    Patent number: 9809796
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: November 7, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Gillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Glycopolysialylation of non-blood coagulation proteins
    Patent number: 9795683
    Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 24, 2017
    Assignees: Lipoxen Technologies Limited, Baxalta Incorporated, Baxalta GmbH
    Inventors: Sanjay Jain, Gregory Gregoriadis, Archana Dwivedi, Srijit Nath, Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Purification of butyrylcholinesterase using membrane adsorption
    Patent number: 9783792
    Abstract: The present invention relates to purification of butyrylcholinesterase using anion exchange material, where the butyrylcholinesterase content is enriched at least 10 fold per total protein in the composition.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: October 10, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Alexander Zaydenberg, Susan Weber, Patrick Gavit, Laura Lei, Wolfgang Teschner, Harald A. Butterweck, Ursula Mais-Paul, Hans-Peter Schwarz
  • Fraction I-IV-1 precipitation of immunoglobins from plasma
    Patent number: 9782477
    Abstract: Among other aspects, the present invention provides methods for the manufacture of blood protein compositions from pooled plasma. In one embodiment, the invention provides an alcohol fractionation scheme that allows for significant increases in the yield of blood proteins purified from the starting plasma sample. In a specific embodiment, a method for fractionating pooled plasma is provided, the method comprising an initial low pH, high alcohol precipitation step. The present invention also provides pharmaceutical compositions of therapeutic blood proteins.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 10, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Bruckschwaiger, Thomas Gundinger, Julia Nuernberger, Wolfgang Teschner, Hans-Peter Schwarz
  • TFPI inhibitors and methods of use
    Patent number: 9777051
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 3, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Animal Protein-Free Media for Cultivation of Cells
    Publication number: 20170267969
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Application
    Filed: May 18, 2017
    Publication date: September 21, 2017
    Applicants: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • VIRUS FILTRATION OF CELL CULTURE MEDIA
    Publication number: 20170260498
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Application
    Filed: March 27, 2017
    Publication date: September 14, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Wolfgang MUNDT, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KREIL
  • Oligopeptide-free cell culture media
    Patent number: 9758568
    Abstract: The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 12, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Artur Mitterer
  • VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE VKORC1, A THERAPEUTIC TARGET OF COUMARIN AND THEIR DERIVATIVES
    Publication number: 20170240867
    Abstract: The invention relates to a novel polypeptide vitamin K epoxide recycling polypeptide (VKORC1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance, wherein the VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.
    Type: Application
    Filed: June 22, 2015
    Publication date: August 24, 2017
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Johannes OLDENBURG, Clemens R. MUELLER-REIBLE, Andreas FREGIN, Simone ROST, Tim-Matthias STROM
  • Formulation of sugar solutions for continuous ultracentrifugation for virus purification
    Patent number: 9732327
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 15, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Nucleophilic catalysts for oxime linkage
    Patent number: 9731024
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 15, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20170224785
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 10, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch